Introduction {#sec1-brainsci-09-00014}
============

Marijuana is the major often abused illegal drug ([Figure 1](#brainsci-09-00014-f001){ref-type="fig"}). The degree of abuse raised from 14.5 million in 2007 to 18.1 million in 2011, with a projected about 5 million adult daily cannabis abusers. Marijuana abuse appears to begin in the eighth grade in 1.3% of children and between 12 and 17 years old in 7.9% of children \[[@B1-brainsci-09-00014]\]. Besides, the typical content of Δ^9^-tetrahydrocannabinol (Δ^9^-THC), which is a major psychoactive component of many bioactive cannabinoids established in the *Cannabis sativa* plant \[[@B2-brainsci-09-00014]\], in marijuana has also doubled from 3.4% in 1993 to 8.8% in 2008 \[[@B3-brainsci-09-00014]\]. Moreover, an upsurge in the concentration of Δ^9^-THC (13.8%) in highly potent plant varieties (sinsemilla, 'skunk') \[[@B3-brainsci-09-00014]\] was also found in this period. The psychological effects that were detected after Δ^9^-THC use are comparable to those observed after recreationally consumed cannabis \[[@B4-brainsci-09-00014]\]. The majority of Δ^9^-THC effects are exerted via the endocannabinoid (EC) system. The EC system comprises receptors for Δ^9^-THC known as cannabinoid receptors type 1 and 2 (CB1R and CB2R, respectively), endogenous receptor ligands ('endocannabinoids', ECs), and EC synthesizing and degrading enzymes \[[@B5-brainsci-09-00014]\]. CB1R is ubiquitously expressed in brain regions, such as the hippocampus, basal ganglia, cortex, amygdala, and cerebellum, all of which are areas connected with the behavioral effects of Δ^9^-THC \[[@B6-brainsci-09-00014]\]. The EC system has a homeostatic role, but its dysfunction can promote pathological conditions \[[@B7-brainsci-09-00014],[@B8-brainsci-09-00014]\].

The CB1Rs and CB2Rs belong to the large superfamily of heptahelical G protein-coupled receptors (GPCR) and couple with G~i~/~o~ proteins (for more details, see reviews \[[@B5-brainsci-09-00014],[@B7-brainsci-09-00014]\]). CB1R is one of the highly abundant GPCRs in the brain, with densities that are similar to the levels of γ-aminobutyric acid (GABA)- and glutamate-gated ion channels \[[@B9-brainsci-09-00014]\]. Functional CB2R is also present in limited amounts and distinct locations in the brains of several animal species, including humans \[[@B10-brainsci-09-00014]\]. The existence of CB2R in the brain has been acknowledged in distinct locations of the CNS in many animal species, including humans, in moderate levels, and is restricted to microglia and vascular elements \[[@B11-brainsci-09-00014]\]. However, the specific functions of this receptor in the CNS are emerging slowly. Recent strong evidence suggests the presence of CB2R mRNA in neuronal cells of the hippocampus \[[@B12-brainsci-09-00014]\] and dopamine-expressing neurons in the ventral tegmental area (VTA) \[[@B13-brainsci-09-00014],[@B14-brainsci-09-00014]\]. CB2R-mediated regulation of cell type-specific synaptic plasticity was shown in the hippocampus \[[@B15-brainsci-09-00014],[@B16-brainsci-09-00014],[@B17-brainsci-09-00014]\]. Furthermore, increased CB2R levels in neurons were noticed under pathological conditions \[[@B18-brainsci-09-00014],[@B19-brainsci-09-00014]\]. The selective agonists and antagonists of CB1R and CB2R are shown in [Figure 2](#brainsci-09-00014-f002){ref-type="fig"} and [Figure 3](#brainsci-09-00014-f003){ref-type="fig"}.

The stimulation of CB1R promotes its interaction with G-proteins, resulting in guanosine diphosphate/guanosine triphosphate exchange and the subsequent dissociation of the α and βγ subunits. These subunits regulate the activity of multiple downstream effector proteins to produce biological functions. CB1Rs are coupled with G~i~ or G~o~ proteins. However, their affinity for G~i~ or G~o~ proteins might vary, as revealed by several receptor ligands and receptor ligand-stimulated GTPγS-binding studies \[[@B20-brainsci-09-00014]\]. CB1R activity differs from several other GPCR-G proteins, as it is precoupled with G-proteins and it is hence constitutively functional in the absence of exogenous agonists \[[@B21-brainsci-09-00014]\]. The CB-mediated signal transduction pathway is shown in [Figure 4](#brainsci-09-00014-f004){ref-type="fig"}. Activation of CB1R by R-(+)-methanandamide (MetAEA) and ECs in N18TG2 cells inhibited adenylate cyclase (AC) activity (for review see \[[@B7-brainsci-09-00014]\]). In certain conditions, the enhanced AC activity was reported without G~i~/~o~ coupling (pertussis toxin-sensitive), probably through the stimulation of G~s~ proteins \[[@B22-brainsci-09-00014]\]. In vitro experiments, the expression of specific isoforms of AC (I, III, V, VI, or VIII) with the coexpression of CB1R was shown to inhibit cyclic adenosine monophosphate (cAMP) accumulation. However, the expression of II, IV, or VII AC isoforms, along with the CB1R coexpression was shown to enhance cAMP accumulation \[[@B23-brainsci-09-00014]\]. Interestingly, whether the coupling of CB1R with G~s~ proteins has physiological function and whether this coupling enhances after G~i~ or G~o~ protein removal through colocalized noncannabinoid G~i~/~o~ protein-coupled receptors have yet to be investigated. Further studies of the mechanism through which CB1R stimulation primes to the buildup of GαGTPβγ heterotrimers would improve our knowledge on the CB1R mediated signal transduction mechanisms. It is also imperative to establish whether these heterotrimers (Gα, Gβγ, and GαGTPβγ) can cooperate with distinct downstream effector targets to afford specificity to the signaling pathways.

CB2R belongs to the seven-transmembrane domain class of GPCRs. CB2R is also coupled to G~i~/~o~ proteins; thus, the stimulation of CB2R is associated with the inhibition of AC and the cAMP/PKA-dependent pathway, as has been observed for CB1R. CB2R stimulation activates MAPK cascades, specifically the ERK and p38 MAPK cascades \[[@B24-brainsci-09-00014]\]. Additionally, the activation of CB2R has also been linked to the stimulation of additional intracellular pathways, including the PI3K/Akt pathway \[[@B24-brainsci-09-00014]\] ([Figure 5](#brainsci-09-00014-f005){ref-type="fig"}). These pathways have been associated with pro-survival effects, as well as with the de novo synthesis of the sphingolipid messenger ceramide \[[@B24-brainsci-09-00014]\], which has been linked to the pro-apoptotic effects of CBs. CB2R activation by the selective agonist AM1241 contributes to the regeneration of DA neurons through increased activation of the PI3K/AKT signaling pathway following MPTP-induced neurotoxicity in mice \[[@B25-brainsci-09-00014]\]. Activation of CB2R by JWH133 induced neuroinflammation by enhancing the expression of MAPK phosphatase-1 (MKP-1), followed by the inhibition of MAPK signaling and increased blood-brain barrier permeability in a rat model of intracerebral hemorrhage (ICH) \[[@B26-brainsci-09-00014]\]. The activation of CB2R is also associated with the activation of CREB, followed by increased expression of Bcl-2, an anti-apoptotic gene leading to decreased cleaved caspase-3 levels and augmented neurological deficits induced by subarachnoid hemorrhage (SAH) in male rats \[[@B27-brainsci-09-00014]\]. The activation of CB2R has been shown to increase G protein-coupled inward rectifying K^+^ (GIRK) channel activity in pyramidal cells \[[@B28-brainsci-09-00014]\]. The activation of CB2R regulates the function of the sodium-bicarbonate cotransporter, causing a hyperpolarization of the neuron in a self-regulatory manner, independent of CB1R activity. These results provide additional evidence for the neuronal expression of CB2Rs and underscore the function of CB2R in neuronal transmission \[[@B17-brainsci-09-00014]\].

SCBs were synthesized as research tools to investigate the function of the EC system \[[@B29-brainsci-09-00014]\]. However, within the last decade, SCBs have been sprayed onto plant material, which has then been packaged and sold as "Spice" or "K2". SBCs are also sold as liquids that can be vaporized and inhaled via e-cigarettes or other devices. These products are also identified as herbal or liquid incenses. These products mimic the effects of marijuana \[[@B30-brainsci-09-00014]\], because SCBs act on the same CB receptors as Δ^9^-THC, the psychoactive component in marijuana. Although these packages are labeled "not for human consumption", these products are often smoked, resulting in a marijuana-like high, as well as other physiological effects. These products are often marketed as safe, legal alternatives to marijuana. They are dangerous and may affect the brain much more strongly than marijuana; their particular effects can be variable and, in some cases, fatal. Many synthetic cannabinoids (SCBs) are now classified as Schedule I drugs under the United States (U.S.) Controlled Substances Act \[[@B31-brainsci-09-00014]\]. Because SCBs are now illegal and are classified in the most dangerous category of scheduled drugs, manufacturers have attempted to circumvent these laws by changing the more structurally diverse cannabimimetic compounds in their mixtures, which might not be listed under scheduled drug regulations. In addition, "medical" marijuana is being legalized in many states across the U.S. Therefore, individuals who previously would not have risked the consequences of procuring an illegal drug might now consider exposing themselves to marijuana and SCBs. In addition, the legal availability of marijuana may decrease use of SCB in the future.

SCBs were classified ([Table 1](#brainsci-09-00014-t001){ref-type="table"}) based on the chemical structures of the molecules \[[@B32-brainsci-09-00014]\]. The pharmacological effects of many SCBs vary widely and have been recently reviewed \[[@B33-brainsci-09-00014]\]. The most frequently investigated SCBs are the aminoalkylindole WIN55,212-2, the cyclohexylphenol CP55,940, and HU-210. Only a few studies have examined the naphthoylindoles (JWH-018 and analogs) or the newer synthetic structural families of cannabinoids that are now dominating the "Spice" market \[[@B33-brainsci-09-00014]\]. SCBs and their metabolites have been found to possess a higher binding affinity for CB receptors than Δ^9^-THC, which implies greater potency, greater harmful effects, and perhaps a longer duration of action. Although most Spice cannabinoids are widely known to be potent CB1R agonists, knowledge of the exact mechanisms that underlie their severe deleterious effects is largely limited. In this review, the authors provide an integrative overview of the current research on the mechanisms that are involved in the detrimental effects of Spice compounds.

Spice products comprise several SCBs, and their potency at CB1R and CB2R differ. Therefore, their signaling mechanisms may also vary. Recently, a list of SCBs detected in Spice products, as well as the effects of these cannabinoids, was reviewed \[[@B33-brainsci-09-00014]\]. Some known physiological effects of SCBs are listed in [Table 2](#brainsci-09-00014-t002){ref-type="table"}. SCBs with a higher affinity for either CB1R or CB2R were shown to elicit adverse neurobehavioral effects. The majority of SCBs found in Spice products ([Table 3](#brainsci-09-00014-t003){ref-type="table"}), such as AM5983, AM678, AM2233, AM2389, SDB-001, AM4054, UR-144, XLR-11, JWH-081, and JWH-073, were shown to have higher affinity for CB1R than CB2R; these SCBs are expected to be similar to Δ^9^-THC in their action and suggested to be more severe than Δ^9^-THC, with some of them displaying other symptoms \[[@B34-brainsci-09-00014]\]. A few SCBs found in Spice products, such as JWH-018, AM1710, and JWH-133, shown to have a higher affinity for CB2R than for CB1R (for references, see (<https://www.drugs-forum.com/forum/showthread.php?t=117873>)). Selected CB1R and CB2R agonists appear to bind off target sites, such as sodium channels, μ and δ opioid receptors, muscarinic acetylcholine receptors, 5-HT~3~ receptors, and glycine receptors (for more details see \[[@B35-brainsci-09-00014]\]). Although details are limited, some designer drugs that are found in spice products have been shown to exert their action through non-CB1R and CB2R targets \[[@B36-brainsci-09-00014],[@B37-brainsci-09-00014],[@B38-brainsci-09-00014]\]. However, the mechanisms by which SCBs instigate their potentially harmful effects are not well established.

JWH-081 produces acute toxicity, as demonstrated by emergency patients, perhaps as a result of strong CB1R activation \[[@B34-brainsci-09-00014]\]. JWH-081 binds to CB1R with high affinity (1.2 nM) \[[@B74-brainsci-09-00014],[@B75-brainsci-09-00014]\]. Bath application (acute) of JWH-081 to hippocampal slices impaired long-term potentiation (LTP). This effect was absent in CB1R KO mice slices. Thus, the adverse effects of JWH-081 on LTP are through CB1R activation. Acute JWH-081 administration in adult mice impairs spontaneous alternation as well as spatial memory in the Y maze and object recognition memory. The participation of pCaMKIV, pCREB, and pERK1/2, which are critical for synaptic plasticity, learning, and memory \[[@B76-brainsci-09-00014]\] in the acute effects of JWH-081 has also been demonstrated. JWH-081 impaired pCaMKIV and pCREB levels in the hippocampi of CB1R WT but not KO mice. JWH-081 decreased pCaMKIV levels in a dose-dependent manner, while the reduced pCREB was found only at a higher dose of JWH-081 (1.25 mg/kg, 30 min). JWH-081 failed to alter pERK levels and total ERK protein levels in the hippocampi of CB1R WT or KO mice. Further, preadministration of the CB1R antagonist SR141716A 30 min before JWH-081 treatment augmented both loss of pCaMKIV and pCREB levels. JWH-081 exhibited greater in vitro and in vivo responses as compared to Δ^9^-THC \[[@B77-brainsci-09-00014]\]. Overall, the CaMKIV-mediated phosphorylation of CREB at Ser133 is crucial for the transcriptional activation of the CREB/CRE-mediated gene expression \[[@B78-brainsci-09-00014]\] and it has been established to play an essential role in memory consolidation and LTP \[[@B76-brainsci-09-00014]\]. Δ^9^-THC significantly reduced the pCREB levels \[[@B79-brainsci-09-00014]\] and another calmodulin kinase-related molecules, such as pCaMKII, in a CB1R-dependent manner \[[@B80-brainsci-09-00014]\]. All Δ^9^-THC metabolites, except one, are inactivated through oxidative metabolism \[[@B81-brainsci-09-00014]\], which block further CB1R stimulation. The higher affinity, potency, and efficacy of JWH-081 \[[@B82-brainsci-09-00014]\], coupled with its likelihood to be metabolized into other metabolites \[[@B83-brainsci-09-00014]\], demonstrates that both the acute and chronic effects of JWH-081 might be more important than those of a similar dose of Δ^9^-THC. Hence, JWH-081 impairs pCaMKIV and pCREB activities through a signaling mechanism downstream of CB1R to elicit potent deleterious neurobehavioral effects in mice ([Figure 6](#brainsci-09-00014-f006){ref-type="fig"}). The SCBs, JWH-018, AM2201, and XLR-11, all inhibit glutamate release and impair LTP in the mouse hippocampus in a CB1R-dependent manner \[[@B49-brainsci-09-00014]\]. JWH-018 and its halogenated derivatives (JWH-018-Cl, JWH-018-Br) dose-dependently impaired both short- and long-memory retention in mice and diminished electrically evoked synaptic transmission, LTP, glutamate, and GABA release in hippocampal slices \[[@B67-brainsci-09-00014]\].

Another derivative of JWH, JWH-018, displays agonistic activity at CB1R (9 nM) and CB2R (2.94 nM) \[[@B84-brainsci-09-00014]\] and it produces the tetrad of behaviors that are classically associated with CBs in rodent models (analgesia, catalepsy, hypomotility, and hypothermia) \[[@B39-brainsci-09-00014],[@B43-brainsci-09-00014]\], but these effects are less potent than those that are associated with JWH-081. Chronic JWH-018 treatment also induces deficits in spatial memory in adolescent mice \[[@B85-brainsci-09-00014]\]. JWH-018 inhibits forskolin-stimulated cAMP production \[[@B86-brainsci-09-00014]\] and has been shown to reduce pERK levels in cultured hippocampal neurons \[[@B48-brainsci-09-00014]\]. While the effects of JWH-081 and JWH-018 are evidently due to CB1R activation, the likely function of CB2R in the effects of compounds that are present in "Spice" and "K2" warrant future investigation.

Another SCB, MAM-2201 (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone, suppressed neurotransmitter release at CB1R-expressing Purkinje cell (PC) synapses in cerebellum slices. MAM-2201 caused more significant inhibition of neurotransmitter release than Δ9-THC and JWH-018. The reduced neurotransmitter release from CB1R-containing PC synapses could contribute to some of the symptoms of SCB intoxication, including impairments in cerebellum-dependent motor coordination and motor learning \[[@B87-brainsci-09-00014]\]. Several SCBs have been shown to be cytotoxic in in vitro studies. SCBs, such as CP-47,497 and CP-47,497-C8, exhibited caspase-3- and CB1R-dependent cytotoxicity in NG 108-15 cells, suggesting that caspase cascades may have a significant function in the apoptosis induced by these SCBs \[[@B88-brainsci-09-00014]\]. XLR-11, at biologically appropriate doses (in the nanomolar range), has been shown to affect mitochondrial function in human proximal tubule (HK-2) cells through a CBR- and eCB-related mechanism. XLR-11 has been shown to induce a transient hyperpolarization of the mitochondrial membrane and enhance ATP production, followed by Bax translocation from the cytosol into the mitochondria. These events cause energy-dependent apoptotic cell death via mechanisms, such as increased caspase-3 activity and chromatin condensation \[[@B89-brainsci-09-00014]\]. Furthermore, JWH-018, JWH-073, and several major human metabolites of these compounds exhibited a high affinity for CB2Rs in CHO-hCB2 cells, suggesting that, when CB2R is available in abundance, these SCBs and their metabolites readily bind to CB2R with high affinity and elicit CB2R signaling \[[@B90-brainsci-09-00014]\]. The SCB AM2201 has been shown to induce epileptic seizures by enhancing CB1R-mediated glutamatergic transmission in the hippocampus \[[@B91-brainsci-09-00014]\].

The SCB CP-47,497-C8 was shown to induce chromosomal damage, suggesting that SCB could cause genetic instability in SCB abusers \[[@B92-brainsci-09-00014]\]. Halogenated derivatives of JWH-018 (JWH-018 Cl and JWH-018 Br) have been shown to impair motor activity and induce catalepsy in mice, and their effects were more severe than those of Δ^9^-THC. When compared to JWH-018, JWH-018Br was less effective at causing seizures, myoclonia, and hyperreflexia. These findings suggest that the halogenated compounds might have been used in the Spice products to produce similar intoxicating effects as JWH-018 while producing fewer side effects \[[@B68-brainsci-09-00014]\]. In another in vivo study, repeated administration of JWH-018 transiently enhanced 5-HT1A receptor sensitivity to produce tolerance to its hypothermic and cataleptic effects \[[@B36-brainsci-09-00014]\]. It has been shown that JWH-018 undergoes extensive metabolism by cytochrome P450 (P450). The major enzyme involved in this metabolism is CYP2C9, a highly polymorphic enzyme that is found largely in the intestines and liver. The polymorphic nature of CYP2C9 results in variable levels of biologically active JWH-018 metabolites in some individuals, offering a mechanistic explanation for the diverse clinical toxicity often observed following JWH-018 abuse \[[@B93-brainsci-09-00014]\]. Recently developed SCBs, such as MMB-FUBINACA, MDMB-FUBINACA, CUMYL-PICA, 5F-CUMYL-PICA, NNEI, and MN-18, exhibited a high affinity for human CB1R and CB2R and produced greater effects than Δ^9^-THC in \[^35^S\] GTPγS binding and cAMP signaling assays. Additionally, all six synthetic cannabinoids replaced Δ^9^-THC in drug discrimination, suggesting that these SCBs may possess subjective effects that are comparable to those of cannabis. Notably, MDMB-FUBINACA, a methylated analog of MMB-FUBINACA, exhibited a higher affinity for CB1R than the parent molecule, suggesting that slight structural alterations could cause a larger impact on the pharmacological properties of these drugs \[[@B65-brainsci-09-00014]\]. AM2201 and XLR-11 resulted in hypothermia in a CB1R-dependent manner in mice \[[@B94-brainsci-09-00014]\]. JWH-018 administration inhibited sensorimotor responses at lower doses, reduced spontaneous locomotion at intermediate/high doses, and induced convulsions, myoclonia and hyperreflexia at high doses in male CD-1 mice. These SCB effects were CB1R-dependent and directly implicated in SCB abuse and driving \[[@B69-brainsci-09-00014]\]. JWH-250 and JWH-073 exhibited nanomolar affinity and potency in in vitro competition binding experiments that were performed on a mouse and human CB1R and CB2R. In vivo administration of either JWH-250 or JWH-073 induced marked hypothermia and increased the pain threshold to both noxious mechanical and thermal stimuli. In addition, it also caused catalepsy, reduced motor activity, impaired sensorimotor responses (visual, acoustic and tactile), caused seizures, myoclonia, and hyperreflexia; and, promoted aggressiveness in male CD-1 mice. Furthermore, a microdialysis study in freely moving mice showed that systemic administration of JWH-250 or JWH-073 stimulated dopamine release in the nucleus accumbens. The CB1R agonist AM251 fully rescued behavioral, neurological, and neurochemical effects. Furthermore, coadministration of ineffective doses of JWH-250 and JWH-073 impaired visual sensory motor responses, augmented the mechanical pain threshold, stimulated mesolimbic DA transmission, and affected other behavioral and physiological parameters \[[@B71-brainsci-09-00014]\]. In other in vivo studies, JWH-018 and AKB48 facilitated spontaneous locomotion in mice. These behavioral effects were inhibited by CB1R and dopamine (DA) D~1~/~5~ and D~2~/~3~ receptor blockade. SPECT-CT studies with dopamine transporter (DAT) revealed that JWH-018 and AKB48 decreased \[^123^I\]-FP-CIT binding in the mouse striatum. Moreover, microdialysis studies showed that the in vivo administration of JWH-018 or AKB48 activated DA release in the nucleus accumbens (NAc) of freely moving mice. These results suggest that JWH-018 and AKB48 induced a psychostimulant effect in mice, possibly by increasing NAc DA release \[[@B72-brainsci-09-00014]\]. In other in vivo studies, 5F-ADBINACA, AB-FUBINACA, and STS-135 caused hypothermia; enhanced pain threshold to both noxious mechanical and thermal stimuli; induced catalepsy; impaired motor activity; resulted in deficits in sensorimotor responses (visual, acoustic, and tactile); induced seizures, myoclonia, and hyperreflexia; and, promoted aggressiveness through CB1R in mice \[[@B70-brainsci-09-00014]\]. However, the visual sensory response that is induced by STS-135 was only partially prevented by AM 251, suggesting an additional CB1R-independent mechanism \[[@B73-brainsci-09-00014]\]. Two recently developed SCBs (AKB48 and 5F-AKB48) exhibited nanomolar affinity and potency at CBRs in mouse and human cell preparations in in vitro competition binding experiments. Administration of AKB48 or 5F-AKB48 in CD-1 mice elicited hypothermia; enhanced the pain threshold to both noxious mechanical and thermal stimuli; induced catalepsy; impaired motor activity; resulted in defects in sensorimotor responses (visual, acoustic and tactile); elicited seizures, myoclonia, and hyperreflexia; and, promoted aggressiveness in mice. Moreover, a microdialysis study in freely moving mice showed that in vivo administration of AKB48 and 5F-AKB48 increased dopamine release in the nucleus accumbens. These behavioral, neurological, and neurochemical effects were inhibited by the administration of a CB1R antagonist (AM 251). Interestingly, a new generation of novel carboxamide synthetic cannabinoids have continued \[[@B61-brainsci-09-00014]\] to appear in the market as marijuana alternatives to evade drug control laws and cannabinoid blood/urine tests. For example, 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) were found to exhibit in vivo cannabinoid-like effects. Although all of these SCBs depressed locomotor activities, the time that is required for them to induce depressive activity varies. For example, 5F-MDMB-PINACA and MDMB-CHIMICA induced (30 min) depression of locomotor activity. ADB-FUBINACA and AMB-FUBINACA depressed locomotor activity for 60--90 min, whereas MDMB-FUBINACA depressed locomotor activity for 150 min. Furthermore, AMB-FUBINACA induced tremors at the highest dose tested. Furthermore, 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA completely replaced the discriminative stimulus effects of Δ^9^-THC following 15-min preadministration. Together, these findings suggest that these SCBs may have abuse potential that is comparable to that of Δ^9^-THC. The AMB-FUBINACA may induce an increased risk of harmfulness in recreational users \[[@B61-brainsci-09-00014]\].

Abused SCBs have been shown to cause convulsion, but the mechanisms are not well understood. A recent study compared the convulsant effects of ∆^9^-THC, JWH-018, and 5F-AB-PINACA as well as that of a classic chemical convulsant pentylenetetrazol (PTZ) using an observational rating scale in mice \[[@B46-brainsci-09-00014]\]. JWH-018 and 5F-AB-PINACA elicited severe convulsions when compared to those elicited by PTZ, and ∆^9^-THC failed to elicit convulsions. SR141716A, but not PTZ, blocked the effects of JWH-018 and 5F-AB-PINACA. Nonselective inhibition of CYP450s with 1-aminobenzotriazole (1-ABT) potentiated the hypothermic effects of JWH-018 and 5F-AB-PINACA and provided protection against the convulsant effects of JWH-018 but not those of 5F-AB-PINACA or PTZ. These findings suggest that SCB-elicited convulsions are facilitated by high intrinsic efficacy at CB1Rs and indicate that drug metabolism plays an essential role in the in vivo efficacy of SCBs. Systemic administration of JWH-073, JWH-210, and Δ^9^-THC failed to affect sensorimotor gating, and locomotor activity was only partially affected. However, Δ^9^-THC, but not JWH-073 and JWH-210, induced an anxiolytic-like effect \[[@B51-brainsci-09-00014]\]. In vitro experiments have suggested that AB-PINACA displays a comparable affinity for CB1Rs but a greater efficacy for G-protein activation and a higher potency for adenylyl cyclase (AC) inhibition than Δ^9^-THC. Chronic administration of AB-PINACA also causes greater desensitization of CB1Rs (e.g., tolerance) than chronic administration of Δ^9^-THC. Notably, monohydroxy metabolites of AB-PINACA retain their affinity and full agonist activity at CB1Rs. Furthermore, the systemic administration of AB-PINACA and 4OH-AB-PINACA caused hypothermia in a CB1R-dependent manner \[[@B62-brainsci-09-00014]\]. These data demonstrate that AB-PINACA exhibits pronounced adverse effects through atypical pharmacodynamic properties at CB1Rs as compared to the effects of Δ^9^-THC by producing metabolically stable active phase I metabolites. These findings indicate that SCBs found in Spice products may exert their acute deleterious effect through CBR. However, a limited number of long-term studies have suggested that SCBs may induce severe harmful effects via complex neuroadaptation mechanisms, and future investigations on this topic are necessary.

In summary, investigation on the psychoactive components of marijuana, as well as the role of the eCB system in humans and its relationship to various brain disorders, has received much attention since the identification of CB receptors and their eCB ligands. Moreover, in addition to the well-known symptoms of euphoria and pleasure, SCBs binding to CB1R can also cause anxiety, short-term memory loss, and attention deficits and can have many other cognitive, affective, and psychomotor effects. The extent to which brain development and functions are disturbed remains unknown in young SCB users who have been shown to develop an increased risk of CB dependence. Although studies on the acute effects of SCBs are underway, studies on the chronic abuse of SCB drugs are still insufficient; thus, this area requires future attention. The immediate results of acute SCBs are probably related to the stimulation of presynaptic CB1R-mediated signaling cascades and the inhibition of the release of several neurotransmitters in the brain. In chronic SCB users, it can be presumed that adaptive changes in the CB1R-mediated signaling cascades and the related neurotransmitter systems result in severe adverse effects. It is likely that the additional compounds that were identified in the Spice/K2 preparations might also contribute, through CB1R or CB2R signaling, to the behavioral effects that are produced by smoking "Spice/K2". In addition, their different pharmacological characteristics might cause the harmful effects of different preparations of "Spice/K2" to vary. Further investigation into these additional SCBs is required. "Spice/K2" is marketed as a "natural" herbal blend but contains at least one very potent SCB that acts through CB1R signaling, which likely accounts for the severe deleterious effects that are elicited by smoking "Spice/K2".
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![Pie illustration outlining the synthetic cannabinoid (SCB) abuse rate among high school-going children. SCB abuse is the most widespread among young people; of the illicit drugs most used by high school seniors, the use of SCBs are second only to that of marijuana (<http://www.drugabuse.gov/publications/drugfacts/spice-synthetic-marijuana>). The most common reasons for using SCBs were affordability, inability to detect SCBs in standard drug tests, and perceived physical and emotional benefits.](brainsci-09-00014-g001){#brainsci-09-00014-f001}

![The structure of natural, endogenous and selective synthetic cannabinoid agonists of Cannabinoid receptors type 1 and type 2 (CB1R and CB2R).](brainsci-09-00014-g002){#brainsci-09-00014-f002}

![The structure of selective CB1R and CB2R antagonists.](brainsci-09-00014-g003){#brainsci-09-00014-f003}

![Schematic illustration of the CB1R mediated signaling. Δ^9^-tetrahydrocannabinol (Δ^9^-THC) and other SCBs produce their effects via binding to CB1Rs, a 7-transmembrane domain G-protein coupled receptor located in the cell membrane. The Ca^2+^ channels inhibited by CB1R stimulation include N-, P/Q-, and L-type channels. The actions on Ca^2+^ channels and adenylyl cyclase (AC) are thought to be mediated by the α subunits of the G-protein, and the effects on G protein-coupled inward rectifying K^+^ (GIRK) and PI3K are considered to be mediated by the βγ subunits. AC inhibition and the subsequent decrease in cyclic adenosine monophosphate (cAMP) lead to the inhibition of cAMP-dependent protein kinase (PKA). This leads to decreased K^+^ channels and pCaMIV and pCREB levels, which might lead to the inhibition of gene expression required for several physiological functions. Stimulatory effects are indicated by (→) symbols and inhibitory effects by (⊥) symbols.](brainsci-09-00014-g004){#brainsci-09-00014-f004}

![A schematic diagram of CB2R mediated signaling. Δ^9^-THC and SCBs also bind to CB2R. Similar to CB1R, CB2R is also a 7-transmembrane domain G-protein coupled receptor that is located in the cell membrane. The activation of CB2R is associated with several distinct cellular processes, such as GIRK, adenylate cyclase (AC), cAMP, PKA, ERK, p38 MAPK, and Akt pathways, as well as the pathway for the de novo synthesis of ceramide. Stimulatory effects are represented by (→) symbols and inhibitory effects by (⊥) symbols.](brainsci-09-00014-g005){#brainsci-09-00014-f005}

![Schematic diagram showing the CB1R signaling mechanism of the SCBs found in Spice products. JWH-081 and JWH-018 both act on CB1R but activate distinct CB1R signaling events. JWH-018, which has a higher affinity for CB2R than for CB1R, reduces pERK1/2. JWH-081, which has a stronger affinity for CB1R than for CB2R, does not affect pERK1/2 but does impair pCaMKIV and pCREB levels, which are linked with Arc gene expression.](brainsci-09-00014-g006){#brainsci-09-00014-f006}
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###### 

The Classification of Cannabinoids (CBs) \[[@B32-brainsci-09-00014]\].

  Class                        Examples
  ---------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classical cannabinoids       Δ^9^-THC, HU-210, AM-906, AM-411, O-1184.
  Non-classical cannabinoids   CP-47,497-C8, CP-55,940, CP-55,244.
  Hybrid cannabinoids          AM-4030.
  Aminoalkylindoles            JWH-018, JWH-073, JWH-398, JWH-015, JWH-122, JWH-210, JWH-081, JWH-200, WIN-55,212, JWH-250, JWH-251, Pravadoline, AM-694, RSC-4.
  Eicosanoids                  Anandamide and methanandamide.
  Others                       Diarylpyrazoles (SR141716A), naphtoylpyrroles (JWH-307), naphthylmethylindenes or derivatives of naphthalene-1-yl-(4-pentyloxynaphthalen-1-yl) methanone (CRA-13).

brainsci-09-00014-t002_Table 2

###### 

Some known physiological effects of synthetic cannabinoids (SCBs) \[[@B33-brainsci-09-00014]\].

  -----------------------------------------------------------
  Raised heart rate & blood pressure
  Altered state of consciousness
  Mild euphoria and relaxation
  Perceptual alterations (time distortion)
  Intensification of sensory experiences
  Pronounced cognitive effects
  Impaired short-term memory
  Agitation, seizures, hypertension, emesis and hypokalemia
  Increase in reaction times
  -----------------------------------------------------------

brainsci-09-00014-t003_Table 3

###### 

Effects of SCBs identified in Spice/K products.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SPCs                                      Dose                       Animal             Exposure                                              Parameter                                                    Effects                                    Reference
  ----------------------------------------- -------------------------- ------------------ ----------------------------------------------------- ------------------------------------------------------------ ------------------------------------------ ------------------------------
  JWH-018                                   3 mg/kg (i.p.)             Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B39-brainsci-09-00014]\]

  0.032 mg/kg (i.v.)                        Monkey                     Acute              Drug discrimination                                   \>Δ^9^-THC                                                   \[[@B40-brainsci-09-00014]\]               

  3 mg/kg (i.p.)                            Rat                        Acute              Drug discrimination                                   \>AM5983\                                                    \[[@B41-brainsci-09-00014]\]               
                                                                                                                                                \>AM2233\                                                                                               
                                                                                                                                                \>WIN 55, 212-2\                                                                                        
                                                                                                                                                \>Δ^9^-THC                                                                                              

  2.5 mg/kg (i.p.)                          Rat                        Acute              Locomotion and catalepsy                              \>Δ^9^-THC                                                   \[[@B42-brainsci-09-00014]\]               

  5.8% (10--50 mg plant material), inhale   Mouse                      Acute              Cannabinoid tetrad                                    \>Δ^9^-THC                                                   \[[@B43-brainsci-09-00014]\]               

  0.1--1.8 μmol/kg (i.v.)                   Mouse                      Acute              Cannabinoid tetrad                                    \>Δ^9^-THC                                                   \[[@B44-brainsci-09-00014]\]               

  0.03--0.3 mg/kg (i.p.)                    Mouse                      Acute              Cannabinoid tetrad                                    Induced                                                      \[[@B45-brainsci-09-00014]\]               

  10 mg/kg (i.p.)                           Mice                       Acute              convulsion                                            Induced                                                      \[[@B46-brainsci-09-00014]\]               

  2 and 3 mg/kg (vapor)                     Human                      Acute              neurocognitive function and subjective feelings       Impaired                                                     \[[@B47-brainsci-09-00014]\]               

  1 and 100 nM                              HP\                        Acute              mEPSC frequency                                       Reduced                                                      \[[@B48-brainsci-09-00014]\]               
                                            Neuron                                                                                                                                                                                                      

  5 nM--5 μM                                Mouse brain slice          Acute              fEPSP                                                 Impaired                                                     \[[@B49-brainsci-09-00014]\]               

  JWH018 4-hydroxyindole metabolite         10 mg/kg (i.p.)            Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B39-brainsci-09-00014]\]

  JWH-167                                   0.1--6.0 μmol/kg (i.v.)    Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-203                                   0.13--13 μmol/kg (i.v.)    Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-204                                   0.8--2 μmol/kg (i.v.)      Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-205                                   13--19 μmol/kg (i.v.)      Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-251                                   0.9--6 μmol/kg (i.v.)      Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-208                                   2.8--38 μmol/kg (i.v.)     Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-237                                   1.5--3.0 μmol/kg (i.v.)    Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  JWH-306                                   1.1--2.9 μmol/kg (i.v.)    Mouse              Acute                                                 Cannabinoid tetrad                                           \>Δ^9^-THC                                 \[[@B44-brainsci-09-00014]\]

  AM2389                                    0.1--0.3 mg/kg (i.p.)      Rat                Acute                                                 Hypothermia and Drug discrimination                          \>AM5983\                                  \[[@B50-brainsci-09-00014]\]
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  AM5983                                    3 mg/kg (i.p.)             Rat                Acute                                                 Drug discrimination                                          \>JWH-018\                                 \[[@B41-brainsci-09-00014]\]
                                                                                                                                                                                                             \>AM2233\                                  
                                                                                                                                                                                                             \>WIN 55, 212-2\                           
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  CP47,497                                  2.5 mg/kg                  Rat                Acute                                                 Locomotion and catalepsy                                     \>JWH-018\                                 \[[@B42-brainsci-09-00014]\]
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  Cannabicyclo-hexanol                      2.5 mg/kg                  Rat                Acute                                                 Locomotion and catalepsy                                     \>CP47,497\                                \[[@B42-brainsci-09-00014]\]
                                                                                                                                                                                                             \>JWH-018\                                 
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  JWH-073                                   3.2--32 mg/kg (i.v.)       Monkey             Acute                                                 Drug discrimination                                          \>Δ^9^-THC                                 \[[@B40-brainsci-09-00014]\]

  0.1--5 mg/kg                              Rat                        Acute              Locomotor activity, Anxiety and Sensorimotor gating   Reduced locomotor activity                                   \[[@B51-brainsci-09-00014]\]               

  JWH-210                                   0.1--5 mg/kg               Rat                Acute                                                 Locomotor activity, Anxiety and Sensorimotor gating          Reduced locomotor activity                 \[[@B51-brainsci-09-00014]\]

  AB-001                                    0.3--30 mg/kg (i.p.)       Mouse              Acute                                                 Hypothermia                                                  \> JWH-018\                                \[[@B52-brainsci-09-00014]\]
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  JWH-081                                   0.625--1.25 mg/kg (i.p.)   mouse              Acute                                                 LTP, Learning and memory                                     Impaired                                   \[[@B53-brainsci-09-00014]\]

  AM-4054                                   0.1--1 mg/kg (s.c.)        Mouse              Chronic                                               Analgesia                                                    Induced antinociception                    \[[@B54-brainsci-09-00014]\]

  AM-4054                                   0.01--0.16 mg/kg (i.p.)    Rat                Acute                                                 Two-choice operant                                           Impaired                                   \[[@B55-brainsci-09-00014]\]

  AM-7418                                   0.03-1 mg/kg (s.c.)        Mouse              Chronic                                               Analgesia                                                    Induced antinociception                    \[[@B54-brainsci-09-00014]\]

  AM-411                                    0.32--1 mg/kg (i.m.)       Monkey             Acute and Chronic                                     Drug tolerance                                               \>WIN 55,212-2\                            \[[@B56-brainsci-09-00014]\]
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  AM-4054                                   0.0032--0.1 mg/kg (i.m.)   Monkey             Acute and Chronic                                     Drug tolerance                                               \>AM-411\                                  \[[@B56-brainsci-09-00014]\]
                                                                                                                                                                                                             \>WIN 55,212-2\                            
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  AM-2201                                   0.1--1 mg/kg (s.c.)        Rat                Acute                                                 Hypothermia and Catalepsy                                    Induced                                    \[[@B57-brainsci-09-00014]\]

  AM-2201                                   20 nM--2μM                 Mouse\             Acute                                                 fEPSP                                                        Impaired                                   \[[@B49-brainsci-09-00014]\]
                                                                       brain slice                                                                                                                                                                      

  UR-144                                    5.6 mg/kg (i.p.)           Mouse              Acute                                                 Cannabinoid tetrad and Drug discrimination                   \>Δ^9^-THC                                 \[[@B58-brainsci-09-00014]\]

  XLR-11                                    5.6 mg/kg (i.p.)           Mouse              Acute                                                 Cannabinoid tetrad and Drug discrimination                   =UR-144\                                   \[[@B59-brainsci-09-00014]\]
                                                                                                                                                                                                             \>Δ^9^-THC                                 

  20 nM--5μM                                Mouse                      Acute              fEPSP                                                 Impaired                                                     \[[@B49-brainsci-09-00014]\]               

  JWH-122                                   0.01--25 µM                Human              Endometrial stromal cell line                         Stress and Cell death                                        Enhanced stress. No effect on cell death   \[[@B60-brainsci-09-00014]\]

  5F-MDMB-PINACA                            1.1 mg/kg (i.p.)           Rat                Acute                                                 Locomotion                                                   Reduced (30 min)                           \[[@B61-brainsci-09-00014]\]

  MDMB-CHIMICA                              0.024 mg/kg (i.p.)         Rat                Acute                                                 Locomotion                                                   Reduced (30 min)                           \[[@B61-brainsci-09-00014]\]

  ADB-FUBINACA                              0.19 mg/kg (i.p.)          Rat                Acute                                                 Locomotion                                                   Reduced (60--90 min)                       \[[@B61-brainsci-09-00014]\]

  AMB-FUBINACA                              0.19 mg/kg (i.p.)          Rat                Acute                                                 Locomotion                                                   Reduced (60--90 min)                       \[[@B61-brainsci-09-00014]\]

  MDMB-FUBINACA                             0.04 mg/kg (i.p.)          Rat                Acute                                                 Locomotion                                                   Reduced (150 min)                          \[[@B61-brainsci-09-00014]\]

  5F-AB-PINACA                              10 mg/kg (i.p.)            Mice               Acute                                                 Convulsion                                                   Induced                                    \[[@B46-brainsci-09-00014]\]

  AB-PINACA                                 1--10 mg/kg (i.p.)         Mice               Acute                                                 Hypothermia                                                  Induced                                    \[[@B62-brainsci-09-00014]\]

  0.2 mg/kg                                 Rat                        Chronic            Learning and memory\                                  Impaired\                                                    \[[@B63-brainsci-09-00014]\]               
                                                                                          Locomotion\                                           Decreased\                                                                                              
                                                                                          Anxiety                                               Decreased                                                                                               

  4-OH-AB-PINACA                            30 and 10 mg/kg (i.p.)     Mice               Acute                                                 Hypothermia                                                  induced                                    \[[@B62-brainsci-09-00014]\]

  5F-AMB                                    300 nM                     Mice mPFC slices   Acute                                                 Excitatory and inhibitory synaptic transmission              Impaired sEPSP, mEPSP, sIPSP and mIPSC     \[[@B64-brainsci-09-00014]\]

  MMB-FUBINACA                              Dose responses (i.p.)      Mice               Acute                                                 Drug discrimination                                          Substituted for THC                        \[[@B65-brainsci-09-00014]\]

  CUMYL-PICA                                Dose responses (i.p.)      Mice               Acute                                                 Drug discrimination                                          Substituted for THC                        \[[@B65-brainsci-09-00014]\]

  5F-CUMYL-PICA                             Dose responses (i.p.)      Mice               Acute                                                 Drug discrimination                                          Substituted for THC                        \[[@B65-brainsci-09-00014]\]

  NNEI                                      Dose responses (i.p.)      Mice               Acute                                                 Drug discrimination                                          Substituted for THC                        \[[@B65-brainsci-09-00014]\]

  MN-18                                     Dose responses (i.p.)      Mice               Acute                                                 Drug discrimination                                          Substituted for THC                        \[[@B65-brainsci-09-00014]\]

  AB-FUBINACA                               4.0 mg/kg (i.p.)           Rat                Chronic                                               Learning and memory\                                         Impaired\                                  \[[@B66-brainsci-09-00014]\]
                                                                                                                                                Locomotion anxiety                                           Decreased\                                 
                                                                                                                                                                                                             Decreased                                  

  AB-CHMINACA                               1.0 mg/kg (i.p.)           Rat                Chronic                                               Hypothermia\                                                 Induced\                                   \[[@B66-brainsci-09-00014]\]
                                                                                                                                                Antinociception\                                             No effect\                                 
                                                                                                                                                Anxiety\                                                     Reduced\                                   
                                                                                                                                                Spatial memory\                                              Impaired\                                  
                                                                                                                                                depression                                                   No effect                                  

  PB-22                                     0.4 mg/kg (i.p.)           Rat                Chronic                                               Hypothermia\                                                 Induced\                                   \[[@B66-brainsci-09-00014]\]
                                                                                                                                                Antinociception\                                             No effect\                                 
                                                                                                                                                Anxiety\                                                     Reduced\                                   
                                                                                                                                                Spatial memory\                                              Impaired\                                  
                                                                                                                                                Depression                                                   Induced                                    

  JWH-018\                                  0.01--1 mg/kg (i.p.)       Mice               Acute                                                 Locomotion\                                                  Impaired\                                  \[[@B67-brainsci-09-00014]\]
  JWH-018-R                                                                                                                                     Learning and memory\                                         Impaired\                                  
                                                                                                                                                LTP                                                          Impaired                                   

  JWH018 Cl\                                0.01--1 mg/kg (i.p.)       Mice               Acute                                                 Hypothermia\                                                 Induced\                                   \[[@B68-brainsci-09-00014]\]
  JWH-018 Br                                                                                                                                    Catalepsy\                                                   Induced\                                   
                                                                                                                                                Locomotion                                                   Impaired                                   

  JWH-018                                   0.01--6 mg/kg (i.p.)       Mice               Acute                                                 Convulsions\                                                 Induced\                                   \[[@B69-brainsci-09-00014]\]
                                                                                                                                                Seizures\                                                    Induced\                                   
                                                                                                                                                Hyperreflexia Myoclonias\                                    Induced\                                   
                                                                                                                                                Visual placing response\                                     Induced\                                   
                                                                                                                                                Visual object response\                                      Reduced\                                   
                                                                                                                                                Acoustic\                                                    Reduced\                                   
                                                                                                                                                Response\                                                    Reduced\                                   
                                                                                                                                                Locomotion                                                   Reduced                                    

  AKB48\                                    0.01--6 mg/kg (i.p.)       Mice               Acute                                                 Convulsions Hyperreflexia Myoclonias\                        Induced\                                   \[[@B70-brainsci-09-00014]\]
  5F-AKB48                                                                                                                                      Catalepsy\                                                   Induced\                                   
                                                                                                                                                Hypothermia\                                                 Induced\                                   
                                                                                                                                                Immobility\                                                  Induced\                                   
                                                                                                                                                Acoustic response\                                           Induced\                                   
                                                                                                                                                Visual placing response\                                     Induced\                                   
                                                                                                                                                DA release                                                   Reduced\                                   
                                                                                                                                                                                                             Reduced\                                   
                                                                                                                                                                                                             Increased                                  

  JWH-250 and JWH-073                       0.01--15 mg/kg (i.p.)      Mice               Acute                                                 Convulsions Hyperreflexia Myoclonias Aggressive responses\   Induced\                                   \[[@B71-brainsci-09-00014]\]
                                                                                                                                                Visual object response\                                      Induced\                                   
                                                                                                                                                Visual placing response\                                     Induced\                                   
                                                                                                                                                Hypothermia\                                                 Induced\                                   
                                                                                                                                                DA release                                                   Induce\                                    
                                                                                                                                                                                                             Induced\                                   
                                                                                                                                                                                                             Reduced\                                   
                                                                                                                                                                                                             Increased                                  

  JWH018\                                   0.03--1 mg/kg (i.p.)       Mice               Acute                                                 Locomotion\                                                  Increased\                                 \[[@B72-brainsci-09-00014]\]
  AKB48                                                                                                                                         DA release                                                   Increased                                  

  5F-ADBINACA AB\                           0.01--6 mg/kg (i.p.)       Mice               Acute                                                 Hypothermia\                                                 Induced\                                   \[[@B73-brainsci-09-00014]\]
  FUBINACA STS-135                                                                                                                              Catalepsy\                                                   Induced\                                   
                                                                                                                                                Locomotion\                                                  Reduced\                                   
                                                                                                                                                Sensorimotor responses\                                      Reduced\                                   
                                                                                                                                                Pain threshold\                                              Increased\                                 
                                                                                                                                                Seizures\                                                    Induced\                                   
                                                                                                                                                Myoclonia Hyperreflexia Aggressiveness                       Induced\                                   
                                                                                                                                                                                                             Induced\                                   
                                                                                                                                                                                                             Increased                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DA: Dopamine; HP: Hippocampus; EPSP: Excitatory postsynaptic potentials; fEPSP: field excitatory postsynaptic potential; mPFC: medial prefrontal cortex; IPSP: inhibitory postsynaptic potential; i.p.: Intraperitoneal; i.v.: intravenous; s.c.: Subcutaneous; i.m.: Intramuscular.
